Vaccinex shares are trading higher after the company reported interim response data in the Phase 1b segment of the KEYNOTE-B84 study of its pepinemab in combination with Merck's KEYTRUDA in patients with recurrent or metastatic head and neck cancer.

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!